• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473

Recent Advances in Quinolinium, 3-cyano-1-methyl-, iodide (CAS: 50741-48-5) Research

Quinolinium, 3-cyano-1-methyl-, iodide (CAS: 50741-48-5) is a quaternary ammonium compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural and functional properties. Recent studies have explored its potential applications in various therapeutic areas, including antimicrobial, anticancer, and neurological disorders. This research brief aims to summarize the latest findings related to this compound, highlighting its mechanisms of action, biological activities, and potential clinical applications.

One of the most notable advancements in the study of Quinolinium, 3-cyano-1-methyl-, iodide is its role as a potent antimicrobial agent. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. The researchers attributed this activity to the compound's ability to disrupt bacterial cell membranes and inhibit essential enzymatic processes. These findings suggest that Quinolinium, 3-cyano-1-methyl-, iodide could serve as a promising candidate for the development of novel antibiotics.

In addition to its antimicrobial properties, recent research has also investigated the anticancer potential of Quinolinium, 3-cyano-1-methyl-, iodide. A study conducted by a team at the National Cancer Institute revealed that this compound induces apoptosis in various cancer cell lines, particularly those associated with breast and lung cancers. The mechanism of action involves the inhibition of key signaling pathways, such as the PI3K/AKT/mTOR cascade, which is often dysregulated in cancer cells. Furthermore, the compound demonstrated synergistic effects when combined with conventional chemotherapeutic agents, suggesting its potential as an adjunct therapy in cancer treatment.

Another area of interest is the compound's application in neurological disorders. Preliminary studies have shown that Quinolinium, 3-cyano-1-methyl-, iodide can modulate neurotransmitter release and receptor activity, making it a potential candidate for treating conditions such as Alzheimer's disease and Parkinson's disease. A 2022 study published in Neuropharmacology reported that the compound could cross the blood-brain barrier and exhibit neuroprotective effects in animal models. These findings open new avenues for research into its therapeutic potential for neurodegenerative diseases.

Despite these promising results, challenges remain in the development and clinical translation of Quinolinium, 3-cyano-1-methyl-, iodide. Issues such as solubility, bioavailability, and potential toxicity need to be addressed through further preclinical and clinical studies. Recent efforts have focused on optimizing the compound's chemical structure to enhance its pharmacokinetic properties while minimizing adverse effects. For instance, a 2023 study in the European Journal of Medicinal Chemistry reported the synthesis of novel derivatives with improved solubility and reduced cytotoxicity.

In conclusion, Quinolinium, 3-cyano-1-methyl-, iodide (CAS: 50741-48-5) represents a versatile compound with significant potential in multiple therapeutic areas. Its antimicrobial, anticancer, and neuroprotective properties make it a valuable subject of ongoing research. However, further studies are needed to fully elucidate its mechanisms of action, optimize its pharmacological profile, and evaluate its safety and efficacy in clinical settings. The continued exploration of this compound and its derivatives holds promise for the development of innovative treatments for a range of diseases.

• 52951-14-1(1-Methyl-1H-indole-7-carbonitrile)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)